Who owns REGULUS THERAPEUTICS INC?
- Ticker: RGLS
- CUSIP Number: 75915k309
Tip: Access positions for across all investors
Analyze quarterly positions in Regulus Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Regulus Therapeutics stock
Who bought or sold REGULUS THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 6.3M | $18M | 100% | Mar 2024 |
|
| Vivo Capital | 5.0M | $14M | 100% | Mar 2024 |
|
| Federated Investors | 3.9M | $5.0M | 0% | Dec 2023 |
|
| Adage Capital Partners GP | 3.7M | $11M | 100% | Mar 2024 |
|
| FMR | 2.9M | $8.4M | 0% | Mar 2024 |
|
| Millennium Management | 1.9M | $5.4M | 100% | Mar 2024 |
|
| Soleus Capital Management | 1.6M | $4.5M | 100% | Mar 2024 |
|
| CVI Holdings | 1.4M | $4.1M | 100% | Mar 2024 |
|
| DAFNA Capital Management | 1.1M | $3.1M | -4% | Mar 2024 |
|
| Alyeska Investment Group | 938k | $2.7M | 100% | Mar 2024 |
|
| Vanguard Group | 740k | $2.1M | 158% | Mar 2024 |
|
| Monashee Investment Management | 625k | $1.8M | 100% | Mar 2024 |
|
| Hudson Bay Capital Management | 625k | $1.7M | 100% | Mar 2024 |
|
| Polar Securities | 536k | $1.5M | 100% | Mar 2024 |
|
| Exome Asset Management | 403k | $1.2M | 126% | Mar 2024 |
|
| Victory Capital Management | 368k | $1.1M | 35% | Mar 2024 |
|
| Goldman Sachs Group | 227k | $655k | 100% | Mar 2024 |
|
| Susquehanna International | 225k | $648k | 539% | Mar 2024 |
|
| Sarissa Capital Management | 185k | $533k | 0% | Mar 2024 |
|
| Opaleye Management | 170k | $491k | 100% | Mar 2024 |
|
| Geode Capital Management | 161k | $463k | 31% | Mar 2024 |
|
| Springbok Capital Management | 133k | $382k | 229% | Mar 2024 |
|
| LPL Financial | 114k | $327k | 100% | Mar 2024 |
|
| Simplex Trading | 76k | $217k | 100% | Mar 2024 |
|
| BlackRock | 68k | $196k | 10908% | Mar 2024 |
|
| Hrt Financial | 63k | $180k | 100% | Mar 2024 |
|
| Citadel Advisors | 39k | $112k | -14% | Mar 2024 |
|
| Morgan Stanley | 28k | $80k | 100% | Mar 2024 |
|
| Balyasny Asset Management | 24k | $70k | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 20k | $57k | 67976% | Mar 2024 |
|
| CTC Alternative Strategies | 19k | $53k | 100% | Mar 2024 |
|
| Commonwealth Equity Services | 18k | $52k | 3% | Mar 2024 |
|
| Northern Trust | 18k | $52k | 0% | Mar 2024 |
|
| Citigroup | 14k | $41k | 567% | Mar 2024 |
|
| Wolverine Trading | 10k | $30k | 100% | Mar 2024 |
|
| Grimes & Company | 10k | $30k | -1% | Mar 2024 |
|
| Group One Trading | 8.6k | $25k | 100% | Mar 2024 |
|
| Tower Research Capital | 3.2k | $9.2k | -10% | Mar 2024 |
|
| Community Bank | 690.00 | $2.0k | 0% | Mar 2024 |
|
| UBS Group | 302.00 | $869.548600 | -12% | Mar 2024 |
|
| Wells Fargo & Company | 142.00 | $402.328600 | 1% | Mar 2024 |
|
| Royal Bank of Canada | 51.00 | $0 | -36% | Mar 2024 |
|
Who sold out of Regulus Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Acadian Asset Management | Sep 2023 | 466.00 | $0 |